These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16156296)

  • 1. Assessment of heparin binding to the AN69 ST hemodialysis membrane: I. Preclinical studies.
    Chanard J; Lavaud S; Paris B; Toure F; Rieu P; Renaux JL; Thomas M
    ASAIO J; 2005; 51(4):342-7. PubMed ID: 16156296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration.
    Lavaud S; Paris B; Maheut H; Randoux C; Renaux JL; Rieu P; Chanard J
    ASAIO J; 2005; 51(4):348-51. PubMed ID: 16156297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.
    Chanard J; Lavaud S; Maheut H; Kazes I; Vitry F; Rieu P
    Nephrol Dial Transplant; 2008 Jun; 23(6):2003-9. PubMed ID: 18156457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AN69 ST haemodialysis membrane under conditions of two different extracorporeal circuit rinse protocols a comparison of thrombogenicity parameters.
    Richtrova P; Opatrny K; Vit L; Sefrna F; Perlik R
    Nephrol Dial Transplant; 2007 Oct; 22(10):2978-84. PubMed ID: 17597089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A heparin-coated dialysis filter (AN69 ST) does not reduce clotting during hemodialysis when compared to a conventional polysulfone filter (F×8).
    Sagedal S; Witczak BJ; Osnes K; Hartmann A; Os I; Eikvar L; Klingenberg O; Brosstad F
    Blood Purif; 2011; 32(3):151-5. PubMed ID: 21659742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AN69: Evolution of the world's first high permeability membrane.
    Thomas M; Moriyama K; Ledebo I
    Contrib Nephrol; 2011; 173():119-129. PubMed ID: 21865784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Membrane biocompatibility in dialysis: the role of absorption].
    Chanard J
    Nephrologie; 2003; 24(7):359-65. PubMed ID: 14650747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology department.
    Gylys KH
    J Cardiovasc Nurs; 2001 Jul; 15(4):91-5. PubMed ID: 11419668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoblast growth inhibition by unfractionated heparin and by low molecular weight heparins: an in-vitro investigation.
    Kock HJ; Handschin AE
    Clin Appl Thromb Hemost; 2002 Jul; 8(3):251-5. PubMed ID: 12361203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
    Fernández JA; Petäjä J; Griffin JH
    Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
    Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
    Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and tinzaparin sodium.
    Dogan OT; Polat ZA; Karahan O; Epozturk K; Altun A; Akkurt I; Cetin A
    Thromb Res; 2011 Oct; 128(4):e29-32. PubMed ID: 21605890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
    Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemocompatibility and anaphylatoxin formation of protein-immobilizing polyacrylonitrile hemodialysis membrane.
    Liu TY; Lin WC; Huang LY; Chen SY; Yang MC
    Biomaterials; 2005 Apr; 26(12):1437-44. PubMed ID: 15482832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of complement activation during extracorporeal blood-biomaterial interaction: effects of heparin coated and uncoated surfaces.
    Kopp R; Mottaghy K; Kirschfink M
    ASAIO J; 2002; 48(6):598-605. PubMed ID: 12455769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.